Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 14/20 | 0.39 |
| ▸ | LOX | P28300 | 5/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | EED | O75530 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | KHK | P50053 | 1/20 | 0.32 |
| ▸ | CETP | P11597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21608061 | 0.94 | MGLL (0.36) | LOXL2LOXMGLLKHKCETP | |
| SCHEMBL21608064 | 0.94 | MGLL (0.36) | LOXL2LOXMGLLKHKCETP | |
| SCHEMBL21607991 | 0.87 | MGLL (0.33) | LOXL2MGLLCETP | |
| SCHEMBL21607983 | 0.87 | MGLL (0.33) | LOXL2MGLLCETP | |
| SCHEMBL21607943 | 0.85 | KCNH2 (0.39) | KCNH2GHSREED | |
| SCHEMBL21607953 | 0.85 | KCNH2 (0.39) | KCNH2GHSREED | |
| SCHEMBL23868379 | 0.85 | LOXL2 (0.37) | LOXL2LOXKCNH2GHSREED | |
| SCHEMBL21608183 | 0.84 | MGLL (0.35) | LOXL2LOXMGLLCETP | |
| SCHEMBL21608177 | 0.84 | MGLL (0.35) | LOXL2LOXMGLLCETP | |
| SCHEMBL21608201 | 0.81 | KDM4E (0.34) | KCNH2GHSREED |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300900-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | US | disclosed |
| WO-2019243531-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300900-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | LOXL2 1639/4885LOX 512/4885KCNH2 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.